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Summary In Austria, 700 women are diagnosed every 
year with ovarian carcinoma. Approximately 15 % of the 
patients with epithelial ovarian cancer have a germline 
mutation in the BRCA1 or BRCA2 genes. The increased 
incidence of breast and/or ovarian cancer in genetically 
related family members has given rise to the term “hered-
itary breast and ovarian cancer syndrome” (HBOC). 
Some 25–55 % of these in-family diseases are attributed 
to germline mutations of BRCA1 or BRCA2, and approxi-
mately 5–10 % to other known tumor predisposition syn-
dromes. The remaining persons may carry mutations in 
as yet unidentified genes. HBOC caused by BRCA1 and 
BRCA2 mutations is an autosomal dominant disorder 
with high penetrance. BRCA1 and BRCA2 encode for so-
called tumor suppressor proteins. Inherited functional 
mutations of these genes cause loss of function of the 
respective allele. Loss of function of the second allele 
causes complete loss of the corresponding protein and 
facilitates the development of a malignancy.
The Association of Gynecologic Oncology recom-
mends that testing for a germline mutation in BRCA1 or 
BRCA2 should be offered to all patients with epithelial 
ovarian cancer. When mutations in BRCA1, BRCA2, or 
other cancer-susceptibility genes have been identified, 
patients with ovarian carcinoma can be treated with new, 
innovative therapies. This recommendation is intended 
as a standard guideline for genetic testing of patients 
with an ovarian carcinoma.
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Empfehlungen der Arbeitsgemeinschaft für 
gynäkologische Onkologie Österreich zur 
genetischen Testung von Patientinnen mit 
Ovarialkarzinom
Zusammenfassung In Österreich erkranken jedes Jahr 
etwa 700 Frauen an einem Ovarialkarzinom. Etwa 15 % 
der Patientinnen mit epithelialem Ovarialkarzinom sind 
Träger einer Keimbahnmutation im BRCA1- oder BRCA2-
Gen. Aufgrund des häufig gemeinsamen Vorkommens 
von Mamma- und Ovarialkarzinomen spricht man vom 
„hereditären Mamma- und Ovarialkarzinomsyndrom“ 
(HBOC). Etwa 25–55 % dieser familiären Erkrankungen 
werden Keimbahnmutationen des BRCA1- oder BRCA2-
Gens zugeschrieben, etwa 5–10 % anderen bekann-
ten Tumordispositionssyndromen. Die verbleibenden 
Erkrankungen werden durch bisher nicht bekannte Gene 
erklärt. BRCA1- und BRCA2-Mutationen werden auto-
somal-dominant mit hoher Penetranz vererbt. Physiolo-
gischerweise kodieren BRCA1 bzw. BRCA2 für sogenannte 
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Tumorsuppressorproteine. Funktionelle Mutationen die-
ser Gene führen zum Ausfall des Allels. Ein Ausfall auch 
des zweiten Allels führt zum Verlust der entsprechenden 
Proteine und erleichtert die maligne Transformation.
Eine genetische Testung und Bestimmung einer 
Keimbahnmutation in BRCA1 oder BRCA2 soll allen 
Patientinnen mit epithelialem Ovarialkarzinom ange-
boten werden. Durch den Nachweis von Mutationen 
im Bereich sogenannter Krebssuszeptibilitätsgene (wie 
BRCA1 und BRCA2) können bei Patientinnen mit mani-
festem Ovarialkarzinom neue, innovative Therapien ein-
gesetzt werden. Durch die vorliegende Empfehlung soll 
die genetische Testung von Patientinnen mit Ovarialkar-
zinom einheitlich definiert werden.
Schlüsselwörter Ovarialkarzinom  · BRCA1  · BRCA2  · 
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Breast carcinomas and ovarian carcinomas
In its guideline issued in May 2011, the Austrian Society 
for Gynecology and Obstetrics took a standpoint on pre-
vention and early diagnosis of breast and ovarian cancers 
in high-risk patients. From this recommendation, the 
indication for molecular genetic analysis of BRCA1 and 
BRCA2 was defined [1]:
Indications for molecular genetic analysis of BRCA1 
and BRCA2
Two breast cancer cases before age of 50 years
Three breast cancer cases before age of 60 years
One breast cancer case before age of 35 years
One breast cancer case before age of 50 years and one ovarian cancer 
case at any age
Two ovarian cancer cases at any age
Male and female breast cancer at any age
This remains the basis for recommending genetic testing 
and meets the criteria for the cost to be paid by the Aus-
trian national medical insurance system.
In Tyrol, Austria, the German S3 Guideline was incor-
porated into the recommendations of the Tyrolean Work-
ing Group for Clinical Oncology (TAKO) [2].
TAKO recommendations:
Only one affected person in a family
Breast cancer with first occurrence before age of 35 years
Bilateral breast cancer with first occurrence before age of 50 years
Both breast and ovarian cancer at any age
Multiple cases on the same side of a family
Two women with breast cancer, one with first occurrence before age of 50 
years
One woman with breast cancer and one woman with ovarian cancer
Two women with ovarian cancer
Three or more women with breast cancer
One man with breast cancer and one woman with breast or ovarian cancer
In general, a greater than 10 % prevalence of the muta-
tion should be the threshold to recommend genetic test-
ing. Even the very conservative National Institute for 
Health and Care Excellence recommends a genetic test 
at a calculated risk of 10 % or more [3].
Until now, the costs for genetic testing in patients with 
an ovarian carcinoma have been covered only when the 
family history was positive, which meant that additional 
family members usually must have been diagnosed with 
ovarian and/or breast cancer. Recent findings, however, 
have shown that up to 15 % of patients with epithelial 
ovarian cancer have germline mutations in BRCA1 or 
BRCA2 [4, 5]. Half of these patients have no apparent 
family history for ovarian cancer. This may be due, on the 
one hand, to the absence of female relatives, and on the 
other hand, to the insufficient knowledge of the family 
medical history.
Germline mutations in BRCA1 or BRCA2 are associ-
ated with early-onset breast cancer. For ovarian can-
cer, the correlation with age is less clear, as 35 % of the 
patients with hereditary ovarian cancer are of the age of 
60 + years at the time of diagnosis.
In addition to germline mutations, at least another 
2–8 % of ovarian cancers have somatic BRCA1 and BRCA2 
mutations [5], so that up to 20 % of patients with ovarian 
cancer have a BRCA1 or BRCA2 deficiency triggered by a 
mutation. In addition, it is also known that 9–14 % of non-
mutated ovarian cancers bear an epigenetic silencing of 
the BRCA1 gene due to promoter hypermethylation [6].
Identification of a BRCA mutation has many conse-
quences. One of them is that patients with a mutation-
induced BRCA dysfunction have better survival and 
respond better to platinum therapy. Furthermore, a 
BRCA germline mutation is also associated with a risk for 
other tumors, particularly breast cancer. Such patients 
can decide to undergo an intensive early detection pro-
gram or prophylactic surgery. Identification of a germline 
mutation also provides important information for other 
family members and their potential tumor risk, and per-
mits personalized preventive measures to be outlined for 
high-risk persons. Genetic testing has taken on special 
importance through the introduction of new therapeu-
tic possibilities using so-called “PARP (Poly ADP ribose 
polymerase) inhibitors” that are particularly effective in 
the case of a BRCA1 or BRCA2 mutation [7].
New technologies such as “next general sequencing” 
reduce the cost of genetic testing and permit additional 
genes to be tested. Blood samples taken in two GOG stud-
ies (GOG 218 and GOG 262) were subjected to genetic 
testing and showed a BRCA1/2 mutation in 13.7 % of the 
patients with ovarian carcinoma, as well as mutations in 
other genes, in particular BRIP1, PALB2, CHEK2, NBN, 
and ATM, in 5.6 % of the patients [8]. The new testing 
methods pose special challenges for interpretation of the 
genetic data, knowledge of a wide range of cancer predis-
positions, and genetic counseling.
On the basis of these new findings, the Association of 
Gynecologic Oncology (AGO) Austria makes the follow-
ing recommendations for women with ovarian cancer:
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ports all innovative steps that promote the use of new 
technologies such as “next generation sequencing” to 
test for not only the two most common mutated genes, 
BRCA1 and BRCA2, but also other genes involved in 
the homologous recombination repair of DNA as well 
as other relevant genes for ovarian cancer biology. 
In addition to testing solely for sequence alterations, 
assays should be developed in the future that also use, 
for example, epigenetic or functional analysis to better 
characterize tumor cells.
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1. Genetic testing for BRCA1 or BRCA2 germline muta-
tions should be offered to all patients with an epi-
thelial ovarian carcinoma. Patients with borderline 
ovarian tumors or nonepithelial ovarian tumors and 
who do not meet the criteria for hereditary breast and 
ovarian carcinoma cannot be expected to benefit from 
testing.
2. Before germline mutation analysis of BRCA1 and 
BRCA2 in genomic DNA, the patient must undergo 
formal genetic counseling with regard to the possibil-
ity of a hereditary predisposition and must give her 
written consent for testing. The test results must be 
explained to the patient in a second personal genetic 
counselling session by a Medical Geneticist or a medi-
cal specialist for the particular indication as defined 
by the Austrian Gentechnikgesetz (GTG, Genetic Engi-
neering Act). Counselling must be concluded with a 
counselling letter that contains all relevant points of 
the discussion, including the relevance of the findings 
for the patient’s family.
3. Before carrying out a genetic analysis of DNA iso-
lated from tumor tissue that may potentially identify 
a germline mutation for example in BRCA1 or BRCA2, 
the patient must be informed of the potential rel-
evance of the test results for herself or other family 
members and must give her written consent for the 
test (for download see: AGO patient information sheet 
at: www.ago-austria.at).
4. If a probable germline mutation is identified in the 
tumor tissue, the test results must be conveyed to the 
patient by genetic counseling in compliance with the 
Austrian GTG. The patient must be informed about 
the relevance of the test results for herself and other 
family members as well as the possibilities for further 
work-up, and she must be offered the opportunity for 
germline mutation testing in genomic DNA (typically 
isolated from blood).
5. In view of the great significance for prognosis and 
treatment, especially, for possible PARP inhibitor ther-
apy, not only a test for germline mutation, using DNA 
from a blood sample, but also quality-controlled test-
ing of the tumor material should be performed. In an 
effort to personalize medicine, the AGO explicitly sup-
